- New drugs to be made available locally for first time
- License and technology transfer agreement completed with Dutch company PharmaMatch BV
- High cholesterol one of major factors in rise of cardiovascular diseases
- Cardiovascular disease UAE’s biggest killer
December 26, 2018, Ras Al Khaimah (UAE) - Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has completed a deal with leading Dutch company, PharmaMatch BV, to launch a novel combination for the treatment of hypercholesterolemia, which is currently unavailable in the UAE market.
The license and technology transfer agreement was signed earlier this month on the sidelines of CPhI Worldwide, the largest pharmaceutical trade fair in the world. Under the terms of the agreement, Julphar will manufacture the combination, which is used to target hypercholesterolemia, a condition characterized by very high levels of cholesterol in the blood.
Commenting on the announcement Jerome Carle, General Manager of Julphar, said, 'Bringing new medicines to the local market is something we are very proud to be able to do. We strongly believe in the efficacy and value of these medications. They will have a real impact on the lives of the many people who suffer with high cholesterol'.
“We are delighted to be partnering with PharmaMatch BV, a company with a strong reputation and track record in the European market and further afield. Our goal at Julphar from the very beginning of our journey has always been to deliver affordable, quality healthcare solutions. Our relationship with PharmaMatch will enable us to continue to make a difference and I can see our relationship continuing to grow and develop into something very positive.”
High blood cholesterol is a condition that causes the levels of certain bad fats, or lipids, to be too high in the blood. High blood cholesterol is one of the major risk factors for cardiovascular diseases (heart diseases), the leading cause of death in the UAE, which accounts for over two-thirds of all deaths in the country.
Cédric Trouillot, Sales Manager at PharmaMatch, said: “PharmaMatch sees its collaboration with Julphar as a very important step towards expanding its contribution in the MENA region.”
CPhI Worldwide took place in Madrid earlier this month and featured 45,000 visitors and more than 2,500 exhibitors covering the end-to-end supply chain from ingredients, APIs, excipients, contract services, packaging, and machinery. It followed the regional debut of CPhI Middle East in September, where Julphar witnessed particularly strong footfall.